Aquestive Therapeutics, Inc. (NASDAQ:AQST) to Post Q1 2023 Earnings of $0.05 Per Share, Oppenheimer Forecasts

Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) – Research analysts at Oppenheimer upped their Q1 2023 EPS estimates for shares of Aquestive Therapeutics in a note issued to investors on Thursday, March 9th. Oppenheimer analyst F. Brisebois now forecasts that the company will post earnings of $0.05 per share for the quarter, up from their previous forecast of ($0.27). The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.78) per share. Oppenheimer also issued estimates for Aquestive Therapeutics’ Q2 2023 earnings at ($0.19) EPS, Q3 2023 earnings at ($0.20) EPS, Q4 2023 earnings at ($0.19) EPS and FY2023 earnings at ($0.52) EPS.

Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last released its earnings results on Wednesday, March 8th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.02). The company had revenue of $10.68 million for the quarter, compared to analyst estimates of $9.93 million. During the same period in the previous year, the company posted ($0.38) earnings per share.

Separately, Wedbush upgraded shares of Aquestive Therapeutics from a “neutral” rating to an “outperform” rating in a report on Thursday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Aquestive Therapeutics has a consensus rating of “Buy” and an average target price of $9.38.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $0.79 on Monday. Aquestive Therapeutics has a 52 week low of $0.62 and a 52 week high of $2.95. The company has a market capitalization of $42.99 million, a price-to-earnings ratio of -0.70 and a beta of 2.69. The company has a 50-day moving average of $0.87 and a 200-day moving average of $0.98.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds have recently made changes to their positions in the business. State Street Corp grew its holdings in shares of Aquestive Therapeutics by 10.3% during the first quarter. State Street Corp now owns 96,037 shares of the company’s stock worth $251,000 after purchasing an additional 8,960 shares in the last quarter. PDT Partners LLC lifted its holdings in shares of Aquestive Therapeutics by 10.7% during the first quarter. PDT Partners LLC now owns 101,456 shares of the company’s stock valued at $265,000 after purchasing an additional 9,845 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Aquestive Therapeutics by 118.2% in the first quarter. BNP Paribas Arbitrage SA now owns 34,810 shares of the company’s stock valued at $91,000 after acquiring an additional 18,860 shares during the period. Geode Capital Management LLC raised its stake in shares of Aquestive Therapeutics by 5.9% in the fourth quarter. Geode Capital Management LLC now owns 387,575 shares of the company’s stock worth $349,000 after buying an additional 21,676 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Aquestive Therapeutics by 204.7% during the first quarter. Renaissance Technologies LLC now owns 34,300 shares of the company’s stock worth $90,000 after purchasing an additional 23,043 shares in the last quarter. 29.35% of the stock is currently owned by institutional investors.

About Aquestive Therapeutics

(Get Rating)

Aquestive Therapeutics, Inc engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.